In addition, in a biomarker analysis of pretreatment tumor samples from the phase 2 IMvigor210 trial, high expression of TGF‐β was associated with lack of response to PD‐L1 blockade with atezolizumab [17]. This evidence concerns the gene TGFB1 and neoplasm.